Drugs / 9MW3811
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05912049 | Jul → Dec 2023 | idiopathic pulmonary fibrosis | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05911984 | Jun 2023 → Mar 2024 | cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05740475 | Mar → Sep 2023 | neoplasm, pulmonary fibrosis | Mabwell (Shanghai) Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07576608 | Dec 2025 → Dec 2026 expected | — | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 9MW3811 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05911984 ↗ |
| Known as | 9MW3811 Injection | “Drug: 9MW3811 Injection” NCT07576608 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized monoclonal antibody” NCT07576608 ↗ |
| Route | Intravenous | “Single dose intravenously infused on day 1” NCT05740475 ↗ |